This company has been acquired
PKBO Stock Overview
A clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of patients with cancer, inflammatory, and rare diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Peak Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.022 |
| 52 Week High | US$0.26 |
| 52 Week Low | US$0.002 |
| Beta | 1.78 |
| 1 Month Change | -55.00% |
| 3 Month Change | n/a |
| 1 Year Change | -71.84% |
| 3 Year Change | -99.77% |
| 5 Year Change | n/a |
| Change since IPO | -99.77% |
Recent News & Updates
Recent updates
Shareholder Returns
| PKBO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -67.9% | 1.7% | -0.9% |
| 1Y | -71.8% | -2.2% | 22.6% |
Return vs Industry: PKBO underperformed the US Biotechs industry which returned 22.2% over the past year.
Return vs Market: PKBO underperformed the US Market which returned 33.1% over the past year.
Price Volatility
| PKBO volatility | |
|---|---|
| PKBO Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.7% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: PKBO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine PKBO's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 6 | n/a | peak-bio.com |
Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of patients with cancer, inflammatory, and rare diseases in the United States. The company’s lead product candidate is PHP-303, which is in Phase 2 clinical study for the treatment of alpha-1 antitrypsin deficiency and acute respiratory distress syndrome. It also develops Trop2 PH1, an antibody-drug-conjugate in preclinical trials for solid tumors.
Peak Bio, Inc. Fundamentals Summary
| PKBO fundamental statistics | |
|---|---|
| Market cap | US$1.62m |
| Earnings (TTM) | -US$3.32m |
| Revenue (TTM) | US$75.19k |
6.9x
P/S Ratio-0.2x
P/E RatioIs PKBO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PKBO income statement (TTM) | |
|---|---|
| Revenue | US$75.19k |
| Cost of Revenue | US$1.63m |
| Gross Profit | -US$1.55m |
| Other Expenses | US$1.77m |
| Earnings | -US$3.32m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.14 |
| Gross Margin | -2,064.31% |
| Net Profit Margin | -4,420.78% |
| Debt/Equity Ratio | -46.3% |
How did PKBO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/11/14 09:45 |
| End of Day Share Price | 2024/11/14 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Peak Bio, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ahu Demir | Ladenburg Thalmann & Company |